Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $171,196 | $114,625 | $103,659 | $97,610 |
| - Cash | $6,933 | $6,338 | $13,424 | $25,019 |
| + Debt | $50,469 | $48,415 | $45,662 | $43,081 |
| Enterprise Value | $214,732 | $156,702 | $135,897 | $115,672 |
| Revenue | $51,390 | $9,057 | $6,094 | $5,762 |
| % Growth | 467.4% | 48.6% | 5.8% | – |
| Gross Profit | $51,390 | $9,057 | $6,094 | $5,762 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $25,939 | -$11,831 | -$13,323 | -$11,757 |
| % Margin | 50.5% | -130.6% | -218.6% | -204% |
| Net Income | $15,843 | -$16,224 | -$17,493 | -$14,901 |
| % Margin | 30.8% | -179.1% | -287.1% | -258.6% |
| EPS Diluted | 0.85 | -0.91 | -0.98 | -0.84 |
| % Growth | 193.4% | 7.1% | -16.7% | – |
| Operating Cash Flow | -$17,614 | -$10,140 | -$11,092 | -$11,445 |
| Capital Expenditures | -$13 | -$11 | -$18 | -$20 |
| Free Cash Flow | -$17,627 | -$10,151 | -$11,110 | -$11,465 |